that PSA was widely recognized as a biomarker of PCa.[4] PSA has since become the most commonly used biomarker in all of oncology, however, several shortcomings with respect to specificity and sensitivity of the assay have been recognized.[5, 6] This has resulted in cases of both under‐ and overtreatment of the disease.[7, 8, 9, 10, 11]. The gene discussed is KLK3; the disease is posterior cortical atrophy.